Literature DB >> 24805070

Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Martin Sarter1, Roger L Albin2, Aaron Kucinski3, Cindy Lustig3.   

Abstract

Falls are a major source of hospitalization, long-term institutionalization, and death in older adults and patients with Parkinson's disease (PD). Limited attentional resources are a major risk factor for falls. In this review, we specify cognitive-behavioral mechanisms that produce falls and map these mechanisms onto a model of multi-system degeneration. Results from PET studies in PD fallers and findings from a recently developed animal model support the hypothesis that falls result from interactions between loss of basal forebrain cholinergic projections to the cortex and striatal dopamine loss. Striatal dopamine loss produces inefficient, low-vigor gait, posture control, and movement. Cortical cholinergic deafferentation impairs a wide range of attentional processes, including monitoring of gait, posture and complex movements. Cholinergic cell loss reveals the full impact of striatal dopamine loss on motor performance, reflecting loss of compensatory attentional supervision of movement. Dysregulation of dorsomedial striatal circuitry is an essential, albeit not exclusive, mediator of falls in this dual-system model. Because cholinergic neuromodulatory activity influences cortical circuitry primarily via stimulation of α4β2* nicotinic acetylcholine receptors, and because agonists at these receptors are known to benefit attentional processes in animals and humans, treating PD fallers with such agonists, as an adjunct to dopaminergic treatment, is predicted to reduce falls. Falls are an informative behavioral endpoint to study attentional-motor integration by striatal circuitry.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylcholine; Basal forebrain; Dopamine; Falls; Striatum

Mesh:

Substances:

Year:  2014        PMID: 24805070      PMCID: PMC4348073          DOI: 10.1016/j.expneurol.2014.04.032

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  187 in total

1.  Cholinergic deafferentation of the neocortex using 192 IgG-saporin impairs feature binding in rats.

Authors:  Leigh C P Botly; Eve De Rosa
Journal:  J Neurosci       Date:  2009-04-01       Impact factor: 6.167

2.  Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain.

Authors:  Laszlo Zaborszky; L Hoemke; H Mohlberg; A Schleicher; K Amunts; K Zilles
Journal:  Neuroimage       Date:  2008-06-07       Impact factor: 6.556

3.  Rats and humans paying attention: cross-species task development for translational research.

Authors:  Elise Demeter; Martin Sarter; Cindy Lustig
Journal:  Neuropsychology       Date:  2008-11       Impact factor: 3.295

Review 4.  Levodopa unresponsive symptoms in Parkinson disease.

Authors:  Kapil Sethi
Journal:  Mov Disord       Date:  2008       Impact factor: 10.338

5.  Effects of neostriatal 6-OHDA lesion on performance in a rat sequential reaction time task.

Authors:  D Domenger; R K W Schwarting
Journal:  Neurosci Lett       Date:  2008-08-22       Impact factor: 3.046

Review 6.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

7.  Impaired attention predicts falling in Parkinson's disease.

Authors:  L M Allcock; E N Rowan; I N Steen; K Wesnes; R A Kenny; D J Burn
Journal:  Parkinsonism Relat Disord       Date:  2008-05-19       Impact factor: 4.891

8.  Executive function and gait in older adults with cognitive impairment.

Authors:  Carol C Persad; Joshua L Jones; James A Ashton-Miller; Neil B Alexander; Bruno Giordani
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-12       Impact factor: 6.053

9.  Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.

Authors:  E Decamp; J S Schneider
Journal:  Brain Res       Date:  2009-02-07       Impact factor: 3.252

10.  Acetylcholine contributes through muscarinic receptors to attentional modulation in V1.

Authors:  J L Herrero; M J Roberts; L S Delicato; M A Gieselmann; P Dayan; A Thiele
Journal:  Nature       Date:  2008-07-16       Impact factor: 49.962

View more
  46 in total

1.  Complex Movement Control in a Rat Model of Parkinsonian Falls: Bidirectional Control by Striatal Cholinergic Interneurons.

Authors:  Cassandra Avila; Aaron Kucinski; Martin Sarter
Journal:  J Neurosci       Date:  2020-06-18       Impact factor: 6.167

Review 2.  What do phasic cholinergic signals do?

Authors:  Martin Sarter; Cindy Lustig; Anne S Berry; Howard Gritton; William M Howe; Vinay Parikh
Journal:  Neurobiol Learn Mem       Date:  2016-02-18       Impact factor: 2.877

Review 3.  Cholinergic double duty: cue detection and attentional control.

Authors:  Martin Sarter; Cindy Lustig
Journal:  Curr Opin Psychol       Date:  2019-01-04

4.  Repetitive mild concussion in subjects with a vulnerable cholinergic system: Lasting cholinergic-attentional impairments in CHT+/- mice.

Authors:  Ajeesh Koshy Cherian; Natalie C Tronson; Vinay Parikh; Aaron Kucinski; Randy D Blakely; Martin Sarter
Journal:  Behav Neurosci       Date:  2019-03-21       Impact factor: 1.912

Review 5.  Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-14       Impact factor: 5.081

6.  The system-neurophysiological basis for how methylphenidate modulates perceptual-attentional conflicts during auditory processing.

Authors:  Nico Adelhöfer; Krutika Gohil; Susanne Passow; Benjamin Teufert; Veit Roessner; Shu-Chen Li; Christian Beste
Journal:  Hum Brain Mapp       Date:  2018-08-22       Impact factor: 5.038

Review 7.  Cholinergic genetics of visual attention: Human and mouse choline transporter capacity variants influence distractibility.

Authors:  Martin Sarter; Cindy Lustig; Randy D Blakely; Ajeesh Koshy Cherian
Journal:  J Physiol Paris       Date:  2016-07-09

Review 8.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 9.  Freezing of gait: understanding the complexity of an enigmatic phenomenon.

Authors:  Daniel Weiss; Anna Schoellmann; Michael D Fox; Nicolaas I Bohnen; Stewart A Factor; Alice Nieuwboer; Mark Hallett; Simon J G Lewis
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

10.  Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.

Authors:  Ajeesh Koshy Cherian; Aaron Kucinski; Ryan Wu; Inge E M de Jong; Martin Sarter
Journal:  Psychopharmacology (Berl)       Date:  2019-01-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.